Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange. When one viewer asks him what's going on with Intel (INTC) after its $16.7 billion deal for Altera (ALTR), Cramer acknowledges that there are people who believe that Intel paid too much for the company. However, Cramer explains why he believes not only is it a good tie-up between the two companies, but Intel is doing what it needed to by being aggressive. In biotech, Cramer advises another viewer not to sell Amgen (AMGN). While it's not one of his 'four horsemen' and he believes Gilead (GILD), Biogen (BIIB), Celgene (CELG) and Regeneron (REGN) are all doing better, Cramer explains that Amgen has some incredible anti-cancer formulations that he's very keen on and he believes investors should stay with the stock. In regard to Costco (COST) after May same-store sales came in flat, Cramer reveals that he believes the stock is a buy here. He explains that a lot of numbers would be looking a lot better if the U.S. dollar was weaker. Another viewer who also read Cramer's book 'Get Rich Carefully,' notes that Baxter International (BAX) is scheduled to break itself up, much like what Cramer outlined the company should do in his book. Cramer says he endorses what Baxter is doing and thinks the company's actions presents an opportunity for investors. Tweet your stock questions @jimcramer using #CramerQ.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.